MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

Pathway analysis using GRB2, a significantly connected and downregulated protein as the focus. by Eiman Y. Ibrahim (10731078)

Matrix crosslinking decreases cell migration persistence. by Michael Pamonag (12295175)

A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

Correlations of cytokines that significantly change between the pre-infusion and post-infusion blood draws pearson’s correlation between cytokine pairs is indicated by color and si... by Jordan K. Abbott (8934239)

Subjects:

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Long COVID prevalence decreases with vaccine uptake in the U.S. by Manlio De Domenico (626037)

“…<p>(A) Prevalence in U.S. states and the U.S. exhibits a decreasing trend with respect to vaccine uptake, both in the population vaccinated with at least one dose (top) and two doses (bottom), with the largest gap between 100% vaccinated and 100% unvaccinated scenarios observed in the reference population of adults who had COVID-19. …”

Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

Decrease of injuries. by Petr Fulin (8380320)

Subjects:

Example of predicted effects of choice bundling on preference for larger, later rewards (LLRs) over smaller, sooner rewards (SSRs). by Jeffrey S. Stein (11689918)

Flowchart of the participants’ progress in the study. by Diego T. Dias (3151332)

Decrease of admissions and lead diagnoses. by Petr Fulin (8380320)

Subjects:

Diagram showing progression to carotid artery stenosis after radiotherapy, including significant and non-significant lesions, clinical presentation, and treatment. by Nawaphan Taengsakul (20642371)

Survival outcomes are improved in canine DLBCL patients receiving chemoimmunotherapy who progress after 90 days. by Katherine Dittrich (16884275)

Sensitivity analyses of seroprevalence with the largest sample size study omitted. by Yu Zhou (89766)

Coagulation parameters in patients receiving and not receiving ancoagulant (AK) therapy at admission. by Ekaterina M. Koltsova (5464523)

Progression-free survival. by Issei Saeki (741994)

“…Patients with AFP ≥ 400 ng/mL had a significantly higher OR rate than those with < 400 ng/mL (28.2 vs. 8.5%, <i>p</i> = 0.011), and there was no significant difference in progression-free survival (PFS) between the two groups. …”

Significant relationships between QOL measures on infusion day and day 7. by Jordan K. Abbott (8934239)

Subjects:

Phase 2 significant effects. by Wendy C. Crone (2262169)

Phase 1 significant effects. by Wendy C. Crone (2262169)